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Abstract
Introduction Obesity is a constantly growing illness in
developed countries and it is strictly related to cardiovas-
cular (CV) diseases, i.e. the main cause of mortality
throughout industralised areas.
Aim to test the ability of trained general physician to
safely and effectively prescribe a very-low carbohydrate
ketogenic (VLCK) diet in clinical practice, with a specific
attention to the effect of this approach on overweight re-
lated CV risk factors (anthropometric measures) blood
pressure, lipid levels, glucose metabolism).
Methods The study has been carried out on a group of
377 patients scattered across Italy and monitored during
1 year. The proposed VLCK diet is a nutritional regimen
characterized by low-fat and low- carbohydrates formula-
tions and a protein content of 1.2/1.5 g/kg of ideal body
weight, followed by a period of slow re-insertion and
alimentary re-education.
Results All the predetermined goals—namely safety, re-
duction of body weight and CV risk factors levels—have
been reached with a significant reduction of body weight
(from baseline to 4 weeks (-7 ± 5 kg, p\0.001), from 4 to
12 weeks (-5 ± 3 kg, p\0.001), no changes from
12 weeks to 12 months; waistline (from baseline to 4 weeks
(-7 ± 4 cm, p\0.001), from 4 to 12 weeks (-5 ± 7 cm,
p\0.001), no changes from 12 weeks to 12 months; fatty
mass (from baseline to 4 weeks (-3.8 ± 3.8 %, p\0.001),
from 4 to 12 weeks (-3.4 ± 3.5 %, p\0.001), no changes
from 12 weeks to 12 months; SBP from baseline to 3 months
(-10.5 ± 6.4 mmHg, p\0.001), no further changes after
1 year of observation).
Conclusion the tested VLCD diet suggested by trained
general physicians in the setting of clinical practice seems
to be able to significantly improve on the middle-term a
number of anthropometric, haemodynamic and laboratory
with an overall good tolerability.
Keywords Ketogenic diet  General practice  Safety 
Cardiovascular risk factors
1 Introduction
Overweight and obesity are pandemic conditions [1] as-
sociated to increased risk for type 2 diabetes, cardiovas-
cular disease, cancer and all cause-mortality [2, 3], and a
dramatic increase in public health expense to their man-
agement [4, 5]. Mediterranean diet seems to be a model to
preserve a good health, especially when followed for the
life-span. However, the large amount of carbohydrate in-
cluded in the modern Mediterranean diet could be not
adequately metabolized in strongly sedentary people and
favor body weight increase [6]. Several randomized clin-
ical trials carried out in specialized medical setting have
clearly shown that a short-term ketogenic diet could be
useful to obtain a quick and relatively safe weight loss in
selected patients [7, 8]. Moreover, the efficacy on body
weight loss seems to be associated to a large number of
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positive metabolic changes, potentially useful to mitigate
the features of the metabolic syndrome and contrasting the
development of type 2 diabetes [9, 10]. In particular, a
recent meta-analysis of randomized clinical trials, showed
that ketogenic diets induce a long-term more significant
improvement in body weight, diastolic blood pressure,
triglycerides and HDL-cholesterol, when compared to low
fat diets [11]. However, there are no many studies testing if
this approach could be useful, feasible and safe also in a
setting of general medicine [12]. This scientific question is
of primary relevance, given the large prevalence of obesity
in general population, that could not be managed in a
hospital setting.
In this context, the aim of our study was to evaluate the
efficacy and tolerability of a ketogenic diet suggested and
monitored in the setting of general practice, in term of long
and mid-term weight loss and modification of the main
cardiovascular (CV) disease risk factors.
2 Methods
General practitioners, well acquainted with VLCK diets
methods selected by a senior physician already expert in
the tested method, after a further specific training, have
carried out this observational study.
The selected patients met the following inclusion re-
quirements: they are aged between 30–69 years, have a BMI
between 27–37 kg/m2 and an abdominal circumference of
98 cm or more for men and 87 cm or more for women.
The exclusion from this study occurred in case of renal
impairment (i.e. creatinine greater or equal to than 1.5 mg/
dL), major depressive with eating disorders, serious hepatic
impairment, insulin-dependent type 1 diabetes, oral anti-
coagulant treatment. Furthermore, patients with an ongoing
anti-cancer treatment as well as pregnant or breast-feeding
women were not taken into account.
The 21.1 % of the subjects was affected by arterial
hypertension, the 10 % by impaired fasting glucose; the
6.4 % by type 2 diabetes, the 3.2 % was in secondary
prevention for cardiovascular diseases. The 12.2 % had
pharmacologically compensated hypothyroidism.
After to have signed a specific informed consent form,
eligible patients, at time zero, were subjected to a general
medical examination and an evaluation of anthropometric
and bio-humoral parameters.
Thirty-seven general practitioners identified, in three
months’ time, 377 eligible patients (M 21.2 %, W 78.8 %).
Among them, 311 were selected, as they were the only
participants to the first monitoring visit at 30 days. Sixty-
six patients dropped-out for different reasons, but none of
which of a clinical matter.
The next monitoring visits were planned first after
3 months and then after 12 months.
The enrolled patients have been subjected to VLCK diet
(as implemented by Lignaform), a nutritional regimen is a
VLCK diet, based on the use of high biological level
protein formulation of milk/egg/legumes origin (peas and
NO OGM soybeans), with a content of 15–18 g in proteins,
2–6 g in carbohydrates, 3 g in fats for a caloric intake of
100 kcal. Additionally, vegetables were allowed. The
preparations were personally bought by patients.
Our method is articulated in different stages: in the first
step we provide a protein intake of 1.2–1.5 g/kg of ideal
body weight [13], in association with low-glycemic index
vegetables. Thus, it is a normal-protein regime compared to
the ideal weight, but hyper-protein diet in relation to the
others nutrients consumed.
Afterwards, the formulations are replaced by natural
protein foods and the diet is gradually completed with other
aliments on the base of glycemic index following a mul-
tiphasic scheme.
Firstly, patients were exclusively treated with formula-
tions and vegetables (stage 1). Then, only one formulation
was replaced by a protein aliment (meat, fish, eggs) and
vegetables (stage 2). Immediately after, another formula-
tion was substituted with another protein food (conclusion
of stage 2). Eventually, patients inserted, in sequential,
fruit, dairy products, cereals and legumes (stages 3–4–5–6).
The duration of each stage is proportional to weight loss
during the ketogenic periods. The last stage (stage 7)
consisted in a re-education to the Mediterranean diet based
on patient’s expenditure of energy.
However, from the very beginning an integration of
calcium, magnesium, potassium, omega 3 fatty acids
(500 mg) and olive oil is necessary.
The following variables have been measured with
standardized methods or calculated at the baseline, at the
monitoring visit at 30 days, then after 3 and 12 months:
height, weight, body mass index (BMI), waist circumfer-
ence (WC), index of central obesity (ICO = ratio of waist
circumference and height), impedentiometrically estimated
fat mass, systolic (SBP), diastolic (DBP) and pulse pressure
(PP), thyroid stimulating hormone (TSH), fasting plasma
glucose (FPG), glycated haemoglobin (HbA1c), total
cholesterol (TC), LDL cholesterol (LDL-C), HDL choles-
terol (HDL-C), triglycerides, liver transaminases, gamma-
glutamyl transferase (gGT), creatinine, estimated
glomerular filtration rate (eGFR, CKD-EPI formula), mi-
croalbuminuria, uric acid (SUA), serum potassium, sodi-
um, magnesium and calcium.
A complete descriptive analysis was carried out for
continuous and categorical parameters. Categorical pa-
rameters were compared by the chi-square test followed by
the Fisher exact test. Normally distributed parameters were
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compared with ANOVA for paired and unpaired samples,
followed by the Student t-test, while not-normally dis-
tributed parameters with Kruskal–Wallys analysis of vari-
ance followed by Mann–Whitney U test. The predictor of a
more significant weight loss were identified by the appli-
cation of a logistic regression test. A significance level of
0.05 has been chosen for all tests. All the analyses were
carried out with the help of SPSS 21.0, version for
Windows.
3 Results
The main characteristics of the enrolled patients are re-
sumed in Table 1. Throughout the study, 82.5 % of the
patients involved in the study, completed the first 4 week
period, 71.1 % the first 12-week period, 52 % continued
the protocol until 12 months.
All the measured anthropometric variables exhibited a
similar trend.
Body weight significantly improved from baseline to
4 weeks (-7 ± 5 kg, p\ 0.001), from 4 to 12 weeks
(-5 ± 3 kg, p\ 0.001), while no changes were ob-
served from 12 weeks to 12 months (-1 ± 2 kg,
p = 0.06). Therefore, after 1 year the subjects experi-
enced a mean total body weight loss of 14 ± 10 kg.
The BMI significantly improved from baseline to
4 weeks (-3 ± 2 kg/m2, p\ 0.001), from 4 to 12 weeks
(-2 ± 2 kg/m2, p\ 0.001), while no changes were ob-
served from 12 weeks to 12 months (-0.2 ± 0.9 kg/m2,
p = 0.08). Therefore, after 1 year the subjects experienced
a mean total body weight loss of 5 ±3 kg/m2.
TheWC significantly improved from baseline to 4 weeks
(-7 ± 4 cm, p\ 0.001), from 4 to 12 weeks (-5 ± 7 cm,
p\ 0.001),while no significant changeswere observed from
12 weeks to 12 months (-0.2 ± 1.1 cm, p = 0.68), so after
1 year the subjects experienced a mean total body weight
loss of 13 ± 7 cm.
The ICOimproved frombaseline to4 weeks (-0.04 ± 0.02,
p\0.001), from 4 to 12 weeks (-0.03 ± 0.04, p\0.001),
while no significant changes were observed from 12 weeks to
12 months (-0.01 ± 0.04, p = 0.64). Therefore after 1 year
the subjects experienced a mean total body weight loss of
0.8 ± 0.4.
The estimated percentage of body fat significantly im-
proved from baseline to 4 weeks (-3.8 ± 3.8 %,
p\ 0.001), from 4 to 12 weeks (-3.4 ± 3.5 %,
p\ 0.001), while no significant changes were observed
from 12 weeks to 12 months (-0.2 ± 1.1 cm, p = 0.89),
therefore after 1 year the subjects experienced a mean total
body weight loss of 8.1 ± 5.9 % (Fig. 1).
Regarding thehaemodynamicparameters, SBPsignificantly
improved from baseline to 3 months (-10.5 ± 6.4 mmHg,
p\0.001) but no changes were observed after 1 year of ob-
servation. A similar trend, has been noticed for DBP
(-2.2 ± 3.1 mmHg, p\0.001) and PP (-8.3 ± 6.2 mmHg,
p\0.001).
FPG significantly improved from baseline to 4 weeks
(-8.7 ± 15.3 mg/dL, p\ 0.001) and no change were ob-
served after 1 year of monitor. Similarly, HbA1c improved
from baseline to 3 months (-0.3 ± 0.7 mg/dL, p\ 0.001)
and held steady after 1 year of observation.
About lipid parameters, LDL-C significantly improved
frombaseline to3 months (-19.5 ± 16.9 mg/dL, p\ 0.001)
and we noticed no change after 1 year of observation. A
similar trend has been observed for TG (-23.4 ± 30.2 mg/
dL, p\ 0.001), while HDL-C improved from baseline to
4 weeks (?1.8 ± 5.6 mg/dL, p = 0.038), and even more
after 12 months (?3.5 ± 3.3 mg/dL, p\ 0.001).
As regards the liver parameters, AST significantly im-
proved from1 to 3 months (-2.2 ± 3.2 U/L, p\ 0.001), and
no other changes were marked after 1 year of observation. A
Table 1 Main anthropometric, haemodynamic and laboratory char-
acteristics of the enrolled subjects at the baseline (value compared
between genders)
Variable Men Women
Age (years) 48.3 ± 10.9* 45.6 ± 9.9
Body weight (kg) 97.5 ± 10.8* 81.9 ± 10.4
Body mass index (kg/m2) 32.1 ± 2.8* 31.2 ± 3.1
Waist circumference (cm) 108.3 ± 9.6* 99.6 ± 10.0
Index of central obesity 0.62 ± 0.05 0.61 ± 0.06
Fat mass (%) 41.4 ± 16.3* 37.3 ± 15.9
Systolic blood pressure (mmHg) 132.5 ± 14.2* 128.0 ± 15.1
Dyastolic blood pressure (mmHg) 78.9 ± 7.7* 75.9 ± 11.3
Pulse pressure (mmHg) 53.5 ± 12.8 52.1 ± 14.6
TSH (uUI/mL) 2.1 ± 1.3 2.6 ± 2.5
Fasting plasma glucose (mg/dL) 104.6 ± 21.8* 95.7 ± 27.0
Glycated haemoglobin (%) 5.5 ± 0.9 5.5 ± 0.8
Total cholesterol (mg/dL) 215.6 ± 35.4 211.8 ± 39.3
HDL cholesterol (mg/dL) 45.2 ± 10.5* 56.3 ± 14.9
LDL cholesterol (mg/dL) 138.7 ± 31.7 132.9 ± 36.1
Triglycerides (mg/dl) 158.9 ± 75.3* 117.0 ± 67.9
AST (U/L) 25.0 ± 10.9* 21.2 ± 7.5
ALT (U/L) 33.3 ± 19.5* 23.4 ± 10.8
Gamma glutamyl transferase (U/L) 32.6 ± 16.9* 23.2 ± 17.4
Creatinine (mg/dL) 0.93 ± 0.15* 0.80 ± 0.15
Serum uric acid (mg/dL) 5.6 ± 1.2* 4.5 ± 1.2
Microalbuminuria (mg/L) 10.3 ± 7.2* 8.9 ± 9.3
Serum potassium (mEq/L) 4.9 ± 1.8 4.3 ± 1.3
Serum sodium (mEq/L) 139.4 ± 3.8 139.2 ± 3.1
Serum magnesium (mg/dL) 2.0 ± 0.6 1.9 ± 0.5
Serum calcium (mg/dL) 8.9 ± 1.2 8.9 ± 1.2
* p\ 0,05, men vs. women
Middle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet 391
similar trend has been observed for ALT (-3.1 ± 5.3 U/L,
p\ 0.001), while gamma-GT improved from baseline to
4 weeks (-4.1 ± 5.2 mg/dL, p\ 0.001), with no other sig-
nificant changes after 1 year of observation.
With reference to renal parameters, estimated
glomerular filtration rate (eGFR), creatinine level and
microalbuminuria were not significantly modified during
the observation period, while uricemia mildly but sig-
nificantly improved from the 3rd month to the end of the
study (-0.4 ± 1.5 mg/dL, p = 0.048).
No significant change has been observed as regards
serum level of potassium, sodium and magnesium. How-
ever calcemia mildly but significantly decreased from
baseline to 30 days (-0.35 ± 0.82 mg/dL, p = 0.001),
while it improved in the following period from 30 to
90 days (?0.21 ± 0.71 mg/dL, p = 0.017).
No changes have been observed in the standard
urinalysis.
The short-term body weight loss was quicker in men
than in women (p\ 0.05), greater in those subjects
experiencing a ketonuria in the first period of diet
(p\ 0.001), and was directly related to the baseline body
weight (RR 1.10, 95 % CI 1.04–1.16, p\ 0.001), and in-
versely to patient age (RR -0.20, 95 % CI -0.27 to-0.15,
p\ 0.001), while the long term body weight loss was
greater in those subjects experiencing a ketonuria in the
first period of diet (p\ 0.05), and was directly related to
the baseline body weight (RR 1.26, 95 % CI 1.27–1.18,
p\ 0.001) and body fat mass (RR 1.17, 95 % CI
1.01–1.33, p = 0.033).
4 Discussion
The international guidelines for cardiovascular disease
prevention suggest, as a first step, the optimization of di-
etary habits in order to improve the cardiovascular disease
risk [14, 15]. In our study, carried out in the setting of
general practice, we observed that a short-term ketogenic
diet is able to improve both on the short and long-term a
Fig. 1 Body weight, BMI, waist circumference, and estimated body fat mass changes during the different study phases
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large number of anthropometric, haemodynamic and
metabolic parameters related to the cardiovascular disease
risk. In particular we examined a significant improvement
in body weight, BMI, WC, ICO, estimated body fat, SBP,
DBP, PP, FPG, HbA1c, LDL-C, TG and HDL-C levels,
that tend to remain stable after 1 year from the end of the
short ketogenic period. The mild improvement of uricemia
observed in the trial could also have some relevant prog-
nostic implication [16].
These changes have not been associated to any clinically
relevant adverse event.
Our results, in terms of body weight and lipid control
improvement, are in good agreement with previous short-
term randomized clinical trials comparing the effect of high
protein diets to standard protein nutritional regimes [17]. A
more recent meta-analysis of 17 randomized clinical trials
involving 1141 obese patients confirmed our observation,
showing that low-carb/high protein diets are also associ-
ated to a significant improvement of systolic and diastolic
BP, basal glycaemia and HbA1c [18]. Beyond the low
intake of carbohydrate, low-fat diets induce improvement
in basal insulinemia depending on protein content in the
diet itself, as high protein diets are associated to improved
insulinemia, and consequently improved glucose metabo-
lism [19]. The long-term positive effects on body weight
and other metabolic parameters observed in our study
could be explained by the maintenance of a low-glycaemic
index diet after the ketogenic hyperproteic period of the
tested method [20]. Nevertheless, our study has a few
relevant limitations worth to be considered.
First, it is not a randomized but an observational clinical
trial. Thus, one can say that observed effects are related to
the reduction of energy intake per se rather than the tested
dietary method [21].
Moreover, one can argue that the baseline characteristics
of the enrolled patients were not homogenous as well as
different physician ability to discuss the methods could
have influenced the efficacy of the method itself. This can
be understood looking at the goal we wanted to reach, that
was to mimic real patients that a general practitioner usu-
ally cope with.
However, at the best of our knowledge, this is the first
report one can find in the literature of the efficacy and tol-
erability of a short-term ketogenic intervention on over-
weight and obese patients outside highly specialized centres,
with a relatively long follow-up after intervention end [22].
5 Conclusion
With the limitation of an observational study, in our ex-
perience a short-term ketogenic diet managed in the setting
of general practice seemed to be able to improve a large
number of anthropometric, haemodynamic and metabolic
parameters related to the cardiovascular disease risk, with
improvements maintained also on the long-term [23, 24].
Further randomized clinical trials are expect to confirm
these positive results.
Acknowledgments Authors gratefully acknowledge Therascience
nutritional laboratory for developing Lignaform method. We feel
indebted to all of the physicians that participated in this study by
collecting data as well as taking care of the patients who took part in
this work. We also thank Alessandra Conte for reading manuscript
and useful suggestions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and
indicate if changes were made.
References
1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono
C, et al. Global, regional, and national prevalence of overweight
and obesity in children and adults during 1980–2013: a system-
atic analysis for the Global Burden of Disease Study 2013.
Lancet. 2014;384:766–81.
2. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA,
Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A
potential decline in life expectancy in the United States in the
21st century. N Engl J Med. 2005;352:1138–45.
3. Koh-Banerjee P, Wang Y, Hu FB, Spiegelman D, Willett WC,
Rimm EB. Changes in body weight and body fat distribution as
risk factors for clinical diabetes in US men. Am J Epidemiol.
2004;159:1150–9.
4. Cicero AF, Rosticci M, D’Addato S, Baronio C, Grossi G, Grandi
E, Borghi C. Population health needs assessment and healthcare
services use in a 3 years follow-up on administrative and clinical
data: results from the Brisighella Heart Study. High Blood Press
Cardiovasc Prev. 2014;21(1):45–51.
5. Finkelstein EA, Ruhm CJ, Kosa KM. Economic causes and
consequences of obesity. Annu Rev Public Health.
2005;26:239–57.
6. Bellisle F. Infrequently asked questions about the Mediterranean
diet. Public Health Nutr. 2009;12:1644–7.
7. Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley
GE. Effects of a high-protein ketogenic diet on hunger, appetite,
and weight loss in obese men feeding ad libitum. Am J Clin Nutr.
2008;87:44–55.
8. Paoli A, Bianco A, Grimaldi KA, Lodi A, Bosco G. Long term
successful weight loss with a combination biphasic ketogenic
Mediterranean diet and Mediterranean diet maintenance protocol.
Nutrients. 2013;5:5205–17.
9. Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets,
glucose homeostasis, and nonalcoholic fatty liver disease. Curr
Opin Clin Nutr Metab Care. 2012;15:374–80.
10. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a
review of the therapeutic uses of very-low-carbohydrate (keto-
genic) diets. Eur J Clin Nutr. 2013;67:789–96.
11. Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-
low-carbohydrate ketogenic diet v. low-fat diet for long-term
Middle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet 393
weight loss: a meta-analysis of randomised controlled trials. Br J
Nutr. 2013;110:1178–87.
12. Paoli A. Ketogenic diet for obesity: friend or foe? Int J Environ
Res Public Health. 2014;11:2092–107.
13. Hoffer LJ, Bistrian BR, Young VR, Blackburn GL, Matthews
DE. Metabolic effects of very low calorie weight reduction diets.
J Clin Invest. 1984;73:750–8.
14. The Task Force for the management of dyslipidaemias of the
European Society of Cardiology (ESC) and the European
Atherosclerosis Society (EAS). ESC/EAS Guidelines for the
management of dyslipidaemias. Eur Heart J.
2011;32:1769–818.
15. The American College of Cardiology, American Heart Asso-
ciation Task force on Practice Guidelines and the Obesity society.
AHA/ACC/TOS Guideline for the management of overweight
and obesity in adults. J Am Coll Cardiol.
2013;2014(63):2985–3023.
16. Cicero AF, Rosticci M, Reggi A, Derosa G, Parini A, Grandi E,
D’Addato S, Borghi C. Relationship between serum uric acid and
electrocardiographic alterations in a large sample of general
population: data from the Brisighella Heart Study. High Blood
Press Cardiovasc Prev. 2014 (Epub ahead of print) PubMed
PMID:25512187.
17. Clifton PM, Bastiaans K, Keogh JB. High protein diets decrease
total and abdominal fat and improve CVD risk profile in over-
weight and obese men and women with elevated triacylglycerol.
Nutr Metab Cardiovasc Dis. 2009;19:548–54.
18. Santos FL, Esteves SS, da Costa Pereira A, Yancy WS Jr, Nunes
JP. Systematic review and meta-analysis of clinical trials of the
effects of low carbohydrate diets on cardiovascular risk factors.
Obes Rev. 2012;13:1048–66.
19. Schwingshackl L, Hoffmann G. Long-term effects of low-fat
diets either low or high in protein on cardiovascular and
metabolic risk factors: a systematic review and meta-analysis.
Nutr J. 2013;12:48.
20. Schwingshackl L, Hoffmann G. Long-term effects of low gly-
cemic index/load vs. high glycemic index/load diets on pa-
rameters of obesity and obesity-associated risks: a systematic
review and meta-analysis. Nutr Metab Cardiovasc Dis.
2013;23:699–706.
21. Moreno B, Bellido D, Sajoux I, Goday A, Saavedra D, Crujeiras
AB, Casanueva FF. Comparison of a very low-calorie-ketogenic
diet with a standard low-caloriediet in the treatment of obesity.
Endocrine. 2014;47:793–805.
22. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism
and cardiovascular disease. Am J Physiol Heart Circ Physiol.
2013;304:H1060–76.
23. Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I,
Gardner CD, Bravata DM. Efficacy and safety of low-carbohy-
drate diets: a systematic review. JAMA. 2003;289:1837–50.
24. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mo-
hammed BS, Szapary PO, Rader DJ, Edman JS, Klein S. A
randomized trial of a low-carbohydrate diet for obesity. N Engl J
Med. 2003;348:2082–90.
394 A. F. G. Cicero et al.
